[ad_1]
asbe
- Pharmaceutical firm Endo (OTCQX:NDOI) mentioned that Blaise Coleman will depart the corporate as President & CEO and from the Board of Directors, efficient on August 29, 2024.
- Scott Hirsch has been appointed to function interim CEO within the transition interval whereas the search is ongoing.
- The Board of Directors has initiated a search for the following CEO and has retained Spencer Stuart, an govt search agency, to help within the search process.
- Mr. Hirsch joined the Endo (OTCQX:NDOI) Board of Directors in April 2024. He has over 20 years of expertise in healthcare, funding administration, and monetary providers and was previously the CEO of Solta Medical.
[ad_2]
Source: Seekingalpha